A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis

Multiple Sclerosis

Volumn 11, Issue 5, 2005, Pages 552-561

  Bourdette, Dennis N ^a,b   Edmonds, E ^c   Smith, C ^d   Bowen, J D ^e   Guttmann, C R G ^f   Nagy, Z P ^f   Simon, J ^g   Whitham, R ^a,b   Lovera, J ^a,b   Yadav, V ^a,b   Mass, M ^a   Spencer, L ^b   Culbertson, N ^b   Bartholomew, R M ^h   Theofan, G ^h   Milano, J ^h   Offner, H ^a,b   Vandenbark, A A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d SWEDISH MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h Orchestra Therapeutics Inc   (United States)

Author keywords

Immunoregulation; Multiple sclerosis; T cell receptor; Vaccine

Indexed keywords

BV13S1 ANTIGEN; BV5S2 ANTIGEN; BV6S5 ANTIGEN; FREUND ADJUVANT; IR 902; LYMPHOCYTE RECEPTOR; NEUROVAX TM; SODIUM CHLORIDE; T LYMPHOCYTE RECEPTOR; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG FORMULATION; ERYTHEMA; FEMALE; HUMAN; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SKIN DISCOLORATION; SKIN INDURATION; URINE INCONTINENCE;

ADULT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 25844508410     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1225oa     Document Type: Article

References (46)

1. Ota K, Matsui M, Milford EL, Macklin GA, Weiner HL, Hafler DA. T cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346: 183-85.
2. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, Fredrikson S et al. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991; 21: 1461-68.
3. Chou YK, Bourdette DN, Offner H, Whitham R, Wang R, Hashim GA et al. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992; 38: 105-14.
4. Kerlero-de-Rosbo N, Ben-Nun A. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. J Autoimmun 1998; 11: 287-99.
5. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179: 973-84.
6. Trotter JL, Damico CA, Cross AH, Pelfrey CM, Karr RW, Fu XT et al. HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides. J Neuroimmunol 1997; 75: 95-103.
7. Hellings N, Baree M, Verhoeven C, D'hooghe MB, Medaer R, Bernard CC et al. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res 2001; 63: 290-302.
8. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990; 247: 718-21.
9. Pender MP, Csurhes PA, Greer JM, Mowat PD, Henderson RD, Cameron KD et al. Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. J Immunol 2000; 165: 5322-31.
10. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-75.
11. Bielekova B, Sung M-H, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 2004; 172: 3893-904.
12. Lunemann JD, Ruckert S, Kern F, Wendling U, vanderZee R, Volk HD et al. Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis. J Neurol 2004; 251: 1111-20.
13. Vandenbark AA, Finn T, Barnes D, Culbertson N, Chou YK, Hicks K et al. Diminished frequency of IL-10 secreting, TCR peptide-reactive T-cells in multiple sclerosis patients may allow expansion of activated memory T-cells bearing the cognate BV gene. J Neurosci Res 2001; 66: 171-76.
14. Buenafe AC, Chou YK, Tsaknaridis LJ, Hicks KS, McMahan R, Watson L et al. Human CD4+CD25+ regulatory T cells induced by a soluble chain T cell receptor (scTCR) antigen. J Neurosci Res 2004; 76: 129-40.
15. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971-79.
16. Antel J, Bania M, Noronha A, Neely S. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. J Immunol 1986; 137: 3436-39.
17. Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, Jolesz FA, Weiner HL. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol 2000; 57: 1183-89.
18. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989; 341: 541-44.
19. Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science (Wash DC) 1989; 246: 668-70.
20. Offner H, Hashim GA, Vandenbark AA. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 1991; 251: 430-32.
21. Offner HHG, Vandenbark AA. Immunity to T cell receptor peptides: theory and applications. Reg Pep 1994; 51: 77-90.
22. Stevens DB, Karpus WJ, Gould KE, Swanborg RH. Studies of VB8 T cell receptor peptide treatment in experimental autoimmune encephalomyelitis. J Neuroimmunol 1992; 37: 123-29.
23. Kumar V, Sercarz EE. The involvement of T cell receptor peptide-specific regulatory CD4+ T cells in recovery from antigen-induced autoimmune disease. J Exp Med 1993; 178: 909-16.
24. Vandenbark AA, Morgan E, Bourdette D, Whitham R, Gold D, Bartholomew R et al. TCR peptide therapy in human autoimmune diseases. Neurochem Res 2001; 26: 713-30.
25. Kotzin BL, Karuturi S, Chou YK, Lafferty J, Forrester JM, Better M et al. Preferential T cell receptor β-chain variable gene use in myelin basic protein-reactive T cell clones from patients with multiple sclerosis. Proc Natl Acad Sci USA 1991; 88: 9161-65.
26. Oksenberg JR, Panzara MA, Begovich AB, Mitchell D, Erlich HA, Murray RS et al. Selection of T-cell receptor V-D-J gene rearrangements with specificity for a MBP peptide in brain lesions of MS. Nature 1993; 362: 68-70.
27. Wilson DB, Golding AB, Smith RA, Dafashy T, Nelson J, Smith L et al. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. J Neuroimmunol 1997; 76: 15-28.
28. Bourdette DN, Whitham RH, Chou YK, Morrison WJ, Atherton J, Kenny C et al. Immunity to T cell receptor peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V 5.2 and V 6.1 CDR2 peptides. J Immunol 1994; 152: 2510-19.
29. Vandenbark AA, Chou YK, Whitham R, Mass M, Buenafe A, Liefeld D et al. Treatment of multiple sclerosis with T cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996; 2: 1109-15.
30. Vandenbark AA, Chou YK, Bourdette DN, Whitham R, Offner H. Immunogenicity is critical to the therapeutic application of T cell receptor peptide. Drug News Persp 1997; 10: 341.
31. Chou YK, Morrison WJ, Weinberg AD, Dedrick R, Whitham R, Bourdette DN et al. Immunity to T cell receptor peptides in multiple sclerosis. II. T cell recognition of Vβ5.2 and Vβ6.1 CDR2 peptides. J Immunol 1994; 152: 2520-29.
32. Chou YK, Weinberg AD, Buenafe A, Bourdette DN, Whitham R, Kaleeba JAR et al. MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR VB CDR2 peptides: comparison with myelin basic protein-specific T cells. J Neurosci Res 1996; 45: 838-51.
33. Bourdette DN, Chou YK, Whitham RH, Buckner J, Kwon HJ, Nepom GT et al. Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity determining region 2 peptides from disease-associated T cell receptor BV genes. J Immunol 1998; 161: 1034-44.
34. Gold DP, Smith RA, Golding AB, Morgan EE, Dafashy T, Nelson J et al. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptide. J Neuroimmunol 1997; 76: 29.
35. Morgan E, Nardo C, Diveley J, Kunin J, Bartholomew R, Moss R et al. Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis. J Neurosci Res 2001; 64: 298-301.
36. Moreland LW, Morgan EE, Adamson TC, Fronek Z, Calabrese LH, Cash JM et al. T cell receptor peptide vaccination in rheumatoid arthritis. A placebo-controlled trial using a combination of Vβ3, Vβ14, and Vβ17 peptides. Arthritis Rheum 1998; 41: 1919-29.
37. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lubin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
38. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11.
39. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
40. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981; 26: 1614.
41. Zamora A, Matejuk A, Silverman M, Vandenbark AA, Offner H. Inhibitory effects of incomplete Freund's adjuvant on experimental autoimmune encephalomyelitis. Autoimmunity 2002; 35: 21-28.
42. Vandenbark AA, Hashim GA, Offner H. Idiotypic regulation directed at T-cell receptor determinants. Chem Immunol 1995; 60: 100-25.
43. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou Y et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005; 81: 45-52.
44. Stone LA, Frank JA, Albert PS, Bash CN, Calabresi PA, Maloni H et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesions frequency as a primary outcome measure. Neurology 1997; 49: 862-69.
45. Miller DN, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MS et al. International Natalizumab Multiple Sclerosis Trial Group. N Engl J Med 2003; 348: 15-23.
46. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-97.